This promotional symposium has been organised and funded by Merck for healthcare professionals from the UK who have a clinical interest in colorectal cancer.
Prescribing Information for **ERBITUX® (cetuximab)** and adverse event reporting information can be accessed **here**.


ERBITUX® CETUXIMAB

MERCK

MERCK SPONSORED SATELLITE SYMPOSIUM
BCOG ANNUAL MEETING 2026

A new era: Recent breakthroughs and future directions in *BRAF* V600E mt mCRC

Friday 6th November 2026, 13:45–14:15
Palm Court Suite, Queen's Hotel,
City Square, Leeds, LS1 1PJ



Join us for Merck's sponsored symposium chaired by **Prof. Richard Wilson**, where the expert faculty will discuss the evolving treatment landscape for patients with *RAS* wt mCRC, **including recent advances in biomarker-driven treatment selection, updated clinical guidance** and **emerging therapeutic strategies**. The faculty will also highlight key clinical evidence and practical insights for treating patients with *BRAF* V600E mt mCRC, focusing on **patient selection** and **real-world decision-making**.

Faculty



Chair: Prof. Richard Wilson

Professor of Gastrointestinal Oncology, School of Cancer Sciences, University of Glasgow; and Honorary Consultant in Medical Oncology, The Beatson West of Scotland Cancer Centre



Dr Mark White

Clinical Senior Research Fellow and Honorary Consultant in Medical Oncology, CRUK Scotland Institute and The Beatson West of Scotland Cancer Centre

Agenda

Time	Session	Speaker
13:45–13:55	**Welcome and introductions: The evolving treatment landscape for *BRAF* V600E mt mCRC patients**	Prof. Richard Wilson
13:55–14:10	**From evidence to experience: Treating patients with *BRAF* V600E mt mCRC**	Dr Mark White
14:10–14:15	**Q&A and panel discussion**	All faculty
14:15	**Meeting summary and close**	Prof. Richard Wilson

Click here to receive the latest promotional content on ERBITUX® from Merck.
Please indicate your interest by granting your ePermission

BRAF, v-Raf murine sarcoma viral oncogene homologue B; EGFR, epithelial growth factor receptor; mCRC, metastatic colorectal cancer; mt, mutant; *RAS,* rat sarcoma viral oncogene homologue; wt, wild-type.

This promotional symposium has been organised and funded by Merck for healthcare professionals from the UK who have a clinical interest in colorectal cancer.

ERBITUX® is indicated for the treatment of patients with EGFR-expressing *RAS* wt mCRC in combination with irinotecan-based chemotherapy, in first-line in combination with FOLFOX, or as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. ERBITUX® is also indicated for the treatment of adult patients with *BRAF* V600E mt mCRC in combination with encorafenib and FOLFOX for the first-line treatment and in combination with encorafenib in patients who have received prior systemic therapy.

Prescribing Information for ERBITUX® (cetuximab) and adverse event reporting information can be accessed here.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Merck Serono Limited. Tel: +44 (0)20 8818 7373 or email: medinfo.uk@merckgroup.com.

UK-ERB-00192 | September 2026